Valérie Jooste

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Anne‐Marie Bouvier · 6 shared papers, 2016–2025 · strength 0.84
   • Paper Survival variability across hospitals after resection for pancreatic adenocarcinoma: A multilevel survival analysis on … DOI 10.1016/j.ejso.2023.03.228↗
   • Paper Surgical patterns of care of pancreatic cancer. A French population-based study. DOI 10.1016/j.ejso.2024.108748↗
   • Paper Author's reply to : Pancreatic cancer : Extension of tumor is associated with timeliness of care and with survival in a… DOI 10.1002/ijc.31264↗
2. Olivier Dejardin · 2 shared papers, 2016–2023 · strength 0.26
   • Paper Survival variability across hospitals after resection for pancreatic adenocarcinoma: A multilevel survival analysis on … DOI 10.1016/j.ejso.2023.03.228↗
   • Paper Pancreatic cancer: Wait times from presentation to treatment and survival in a population-based study. DOI 10.1002/ijc.30166↗
3. Alexandre Thobie · 1 shared paper, 2023 · strength 0.19
   • Paper Survival variability across hospitals after resection for pancreatic adenocarcinoma: A multilevel survival analysis on … DOI 10.1016/j.ejso.2023.03.228↗
4. Guillaume Goebel · 1 shared paper, 2025 · strength 0.18
   • Paper Surgical patterns of care of pancreatic cancer. A French population-based study. DOI 10.1016/j.ejso.2024.108748↗
5. A.S. Woronoff · 1 shared paper, 2025 · strength 0.18
   • Paper Surgical patterns of care of pancreatic cancer. A French population-based study. DOI 10.1016/j.ejso.2024.108748↗
6. Sylvain Manfrédi · 1 shared paper, 2022 · strength 0.16
   • Paper Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. DOI 10.3390/cancers14071675↗
7. Côme Lepage · 1 shared paper, 2022 · strength 0.16
   • Paper Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. DOI 10.3390/cancers14071675↗
8. Olivier Facy · 1 shared paper, 2022 · strength 0.16
   • Paper Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. DOI 10.3390/cancers14071675↗
9. François Ghiringhelli · 1 shared paper, 2022 · strength 0.16
   • Paper Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. DOI 10.3390/cancers14071675↗
10. Antoine Drouillard · 1 shared paper, 2017 · strength 0.08
    • Paper Focus on an unusual rise in pancreatic cancer incidence in France. DOI 10.1093/ije/dyx088↗
11. S. Gourgou-Bourgade · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
12. Franck Bonnetain · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
13. Christos Dervenis · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
14. Laëtitia Dahan · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
15. Emmanuel Mitry · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
16. Patrick Pessaux · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
17. Roberto Labianca · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
18. Thierry Conroy · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
19. Jean‐Robert Delpéro · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
20. Paula Ghaneh · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
21. Josep M. Tabernero · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
22. Geertjan van Tienhoven · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
23. Bengt L. G. Glimelius · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
24. Alain Sauvanet · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗
25. David Malka · 1 shared paper, 2014 · strength 0.03
    • Paper Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (… DOI 10.1016/j.ejca.2014.07.011↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.